News

Today, Myogenica, a startup from the University of Minnesota, announced that the U.S. Food and Drug Administration has approved their Investigational New Drug application for MyoPAXon. This product, derived from induced pluripotent stem cells

Scilex Holding Company has announced a Memorandum of Understanding for a collaboration agreement with ACEA, a China-based company focused on innovative treatments for high unmet needs.

Cardurion Pharmaceuticals, a biotechnology company in the clinical stage, has announced a successful Series B financing round raising $260 million. Leading the round was Ascenta Capital, joined by new investors

Lexeo Therapeutics, Inc., a company specializing in genetic medicine, has shared positive interim results for LX2006 in treating Friedreich ataxia cardiomyopathy. The findings from both the Lexeo SUNRISE-FA Phase 1/2 trial

Cytonics Corporation has initiated enrollment for its Phase 1 clinical trial of CYT-108, a novel variant of alpha-2-macroglobulin (A2M) aimed at addressing cartilage degradation in osteoarthritis (OA). This engineered protein targets proteases

AbbVie has applied to the U.S. Food and Drug Administration and European Medicines Agency for approval of upadacitinib (RINVOQ®; 15 mg, once daily) to treat giant cell arteritis (GCA) in adults.

Tiba Biotech LLC, headquartered in Cambridge, has announced a new collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services

Abeona Therapeutics Inc., a company specializing in cell and gene therapy using adeno-associated virus (AAV) technology, and Beacon Therapeutics, a Syncona-backed firm focusing on ophthalmic gene therapies, have announced a collaboration

HepaRegeniX GmbH, a clinical-stage company focused on developing innovative regenerative therapies for acute and chronic liver diseases, has successfully closed a Series C funding round, raising €15 million

Exscientia plc has recently announced an extended partnership with Amazon Web Services to enhance its drug discovery and automation platform using AWS's artificial intelligence